| Drug Type Monoclonal antibody | 
| Synonyms SM17单克隆抗体, SM17 | 
| Target | 
| Action modulators, inhibitors | 
| Mechanism IL-25 modulators(interleukin 25 modulators), IL17RB inhibitors(Interleukin-17 receptor B inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Dermatitis, Atopic | Phase 1 | China  | 21 Nov 2023 | |
| Moderate Atopic Dermatitis | Phase 1 | China  | 21 Nov 2023 | |
| Severe Atopic Dermatitis | Phase 1 | China  | 21 Nov 2023 | |
| Asthma | Phase 1 | United States  | 14 Jun 2022 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | China  | 10 Jan 2019 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | United Kingdom  | 10 Jan 2019 | 
| Phase 1 | - | - | bzshhyrhmf(ufjvrgrlmm) = jqpaeijdnx hnsomdhauw (gqukwifwmp ) View more | Positive | 14 Oct 2025 | 






